PUBLISHER: Grand View Research | PRODUCT CODE: 2151517
PUBLISHER: Grand View Research | PRODUCT CODE: 2151517
The global syndromic infectious disease testing market size was valued at USD 4.7 billion in 2025 and is projected to grow from USD 5.0 billion in 2026 to USD 7.1 billion by 2033, at a CAGR of 5.2% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.1% in 2025. Market growth is primarily driven by the increasing adoption of rapid multiplex molecular diagnostics to enable timely clinical decision-making, as healthcare providers increasingly require faster, more comprehensive identification of infectious pathogens.
Syndromic testing enables the simultaneous detection of multiple bacterial, viral, fungal, and parasitic targets associated with a defined clinical syndrome.
Syndromic testing helps clinicians shorten diagnostic turnaround times and initiate more appropriate treatment strategies.
Global Syndromic Infectious Disease Testing Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends and opportunities in each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global syndromic infectious disease testing market report based on the product, technology, application, end use, and region.